Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split – Yahoo Finance


Salt Lake City, Utah–(Newsfile Corp. – September 26, 2022) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) announced that its stockholders authorized a reverse stock split of the Company’s common stock. Following the annual stockholder meeting, the board of directors approved a reverse stock split of one share of common stock for every 40 shares of common stock. On The NASDAQ Capital Market, trading on a split-adjusted basis is expected to begin on Tuesday, September 27, 2022.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company, except for minor changes due to the treatment of fractional shares as described below. Following the reverse stock split, the Company’s total common shares outstanding will be reduced to approximately 1,079,078 shares. The number of authorized shares of the Company’s common stock will remain at 50,000,000 and the par value will remain $0.01. The reverse stock split will also cause a proportional reduction in the number of warrants and stock options along with an associated increase in exercise prices. No fractional shares will be issued following the reverse stock split, and cash will be paid to holders in lieu of any fractional shares. The new CUSIP number for the common stock following the reverse stock split is 49721T 309.
The Company has retained its transfer agent, VStock Transfer, LLC (“VStock”), to act as exchange agent for the reverse stock split. VStock will manage the exchange of pre-split shares for post-split shares. Stockholders of record will receive a letter of transmittal providing instructions for the exchange of their shares. Stockholders who hold their shares in street name will be contacted by their banks or brokers with any instructions. For further information, stockholders and securities brokers should contact VStock by email at [email protected] or by telephone at (212) 828-8436.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (“OPRA”). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the anticipated effective date of the reverse stock split, the number of shares of stock outstanding following the reverse stock split, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora’s development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading “Risk Factors” contained in Kiora’s Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora’s other public filings. Kiora’s results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
Investor Contact
Francina Agosti, PhD
(617) 546-0742
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/138300
Related Quotes
NLY vs. HASI: Which Stock Is the Better Value Option?
The mortgage REIT completed a reverse split on Friday, so it's the first trading day post-split. A stock decline in this situation isn't odd at all.
Koss Corporation ( NASDAQ:KOSS ) shareholders have seen the share price descend 25% over the month. But in stark…
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if…
Insiders who bought US$301k worth of Physicians Realty Trust's ( NYSE:DOC ) stock at an average buy price of US$16.47…
The 86-year-old investing legend has spoken. Pay attention.
In this article, we will take a look at the 10 Quality Stocks to Buy with Shares Down Over 30% YTD. To skip our analysis of the iShares MSCI USA Quality Factor ETF, its performance, and weighting of the components, you can go directly to see the 5 Quality Stocks to Buy with Shares Down […]
The selling in stock markets looks poised to continues, warns veteran strategist Sam Stovall.
(Bloomberg) — John Paulson became a billionaire after his hedge fund effectively shorted more than $25 billion of mortgage securities at the dawn of the global financial crisis. As he sizes up yet another frothy housing market some 15 years later, the founder of Paulson & Co. says another downturn in US home prices may be in the cards — but the banking system is in a much better condition to handle it. Paulson sat down with Bloomberg for a wide-ranging interview at the Union League of Philadel
In the early days of the pandemic, if there was one coronavirus vaccine stock investors were betting on, it was Novavax (NASDAQ: NVAX). The biotech stock soared more than 2,700% in 2020 as it developed its vaccine candidate. In the same timeframe, Pfizer shares hardly budged.
Dow Jones futures were little changed ahead of Tuesday's open. The Dow Jones Industrial Average finished in a bear market Monday.
Yahoo Finance Live's Seana Smith checks out several trending stocks in the after-hours trading session.
Investors are trying to decide if Volkswagen's new joint venture is good or bad news for QuantumScape.
Shares of the big-data software company Palantir (NYSE: PLTR) gained as much as 5.8% today after the company announced that the Department of Homeland Security renewed a five-year contract with the company. Palantir's stock was up by 2.8% as of 3:20 p.m. ET. Palantir's stock initially got a boost this morning after the company said that the Department of Homeland Security renewed its contract to support Homeland Security Investigations (HSI) using the company's software.
In this article, we discuss the 10 best oil stocks to buy according to hedge funds. If you want to read about some more oil stocks, go directly to 5 Best Oil Stocks To Buy According To Hedge Funds. The oil sector has rebounded from the lows of the pandemic this year and prices have […]
With time, Shopify (NYSE: SHOP) has the potential to be one of them. Diving into the numbers shows how much momentum the company has lost and what it can do to turn things around. The company bet — by hiring staff and building out infrastructure — that the pandemic permanently accelerated e-commerce by five to 10 years.
Morgan Stanley’s Wilson said every 1% change in the Dollar Index has a negative 0.5% impact on S&P 500 earnings. He also saw an approximate 10% headwind to growth to companies earnings in the fourth quarter, in addition to other headwinds such as payback in demand and higher costs from inflation.
Zacks.com users have recently been watching Energy Transfer LP (ET) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Shares of enterprise software star Snowflake (NYSE: SNOW) fell today, down 4.1% as of the end of trading — much more than the broader markets. Snowflake is perhaps one of the best-performing businesses in the enterprise software space. The Federal Reserve held its September meeting last week, whereby Fed governors gave their projections for interest rates hikes in the near and medium term.
Intel (INTC) closed at $26.97 in the latest trading session, marking a -2% move from the prior day.

source


Leave a Reply

Your email address will not be published.